Cookies Policy
X

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

I accept this policy

Find out more here

The clinical developments and future of the COX-2 inhibitor drugs

No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.

Brill’s MyBook program is exclusively available on BrillOnline Books and Journals. Students and scholars affiliated with an institution that has purchased a Brill E-Book on the BrillOnline platform automatically have access to the MyBook option for the title(s) acquired by the Library. Brill MyBook is a print-on-demand paperback copy which is sold at a favorably uniform low price.

Access this article

+ Tax (if applicable)
Add to Favorites
You must be logged in to use this functionality

image of Inflammopharmacology

A new era of analgesia began with the discovery of aspirin in 1899. Since that time, many newer NSAIDs (non-steroid anti-inflammatory drugs) have been discovered and utilized in clinical practice. The mechanism of anti-inflammatory action of NSAIDs is believed to result from inhibition of the enzyme cyclooxygenase (COX), discovered in the 1970s. This enzyme represents the key ratelimiting step in the production of prostaglandins (PGs) from arachidonic acid. Since PGs are essential for normal gastrointestinal, renal, and platelet function, as well as mediating the inflammatory process, inhibition of cyclooxygenase has both beneficial and deleterious effects. The beneficial effect, obviously, is inhibition of the inflammatory process, while the harmful effects comprise an increased incidence of upper gastrointestinal toxicity (ulceration, perforation, and bleeding) as well as possible renal and platelet dysfunction. In the late 1980s, it was discovered that two isoforms of cyclooxygenase existed (COX-1 and COX-2). COX-1 represents a constitutive form that is expressed in most tissues. In contrast, COX-2 is induced at sties of inflammation and also occurs under normal circumstances in the brain and renal tissues. Since COX-2 levels increase dramatically during acute and chronic inflammation, it was hypothesized that the COX-2 inhibitors might offer significant antiinflammatory qualities with reduced toxicity and may have utility in central nervous system mediated conditions other than peripheral pain, including dementias such as Alzheimer's disease and headache, specifically, migraine headache.

Affiliations: 1: San Francisco Clinical Research Center, 909 Hyde Street, Suite 322, San Francisco, California, CA 94109, USA

10.1163/156856001300248362
/content/journals/10.1163/156856001300248362
dcterms_title,pub_keyword,dcterms_description,pub_author
6
3
Loading
Loading

Full text loading...

/content/journals/10.1163/156856001300248362
Loading

Data & Media loading...

http://brill.metastore.ingenta.com/content/journals/10.1163/156856001300248362
Loading

Article metrics loading...

/content/journals/10.1163/156856001300248362
2001-05-31
2016-12-10

Sign-in

Can't access your account?
  • Tools

  • Add to Favorites
  • Printable version
  • Email this page
  • Subscribe to ToC alert
  • Get permissions
  • Recommend to your library

    You must fill out fields marked with: *

    Librarian details
    Your details
    Why are you recommending this title?
    Select reason:
     
    Inflammopharmacology — Recommend this title to your library
  • Export citations
  • Key

  • Full access
  • Open Access
  • Partial/No accessInformation